Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil EL&P Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Glaukos Corp (NY: GKOS ) 132.25 UNCHANGED Streaming Delayed Price Updated: 7:00 PM EDT, Oct 31, 2024 Add to My Watchlist Quote Overview Detailed Quote Charting Historical Prices News All News News Headlines Press Releases Research Quarterly Reports Insider Filings Other Filings Headline News about Glaukos Corp < Previous 1 2 3 4 5 Next > How Is The Market Feeling About Glaukos? October 30, 2024 Via Benzinga A Closer Look at 7 Analyst Recommendations For Glaukos October 14, 2024 Via Benzinga Navigating 11 Analyst Ratings For Glaukos August 28, 2024 Via Benzinga Glaukos Stock: A Deep Dive Into Analyst Perspectives (12 Ratings) August 01, 2024 Via Benzinga Meta To Rally Around 35%? Here Are 10 Top Analyst Forecasts For Thursday August 01, 2024 Via Benzinga GKOS Stock Earnings: Glaukos Misses EPS, Beats Revenue for Q2 2024 July 31, 2024 GKOS stock results show that Glaukos missed analyst estimates for earnings per share but beat on revenue for the second quarter of 2024. Via InvestorPlace 10 Analysts Have This To Say About Glaukos July 10, 2024 Via Benzinga Deep Dive Into Glaukos Stock: Analyst Perspectives (12 Ratings) May 22, 2024 Via Benzinga Analyst Ratings For Glaukos April 08, 2024 Via Benzinga 5 Analysts Have This To Say About Glaukos March 22, 2024 Via Benzinga 7 Leading MedTech Stocks for Next-Gen Health Solutions July 31, 2024 With healthcare innovations promising to deliver groundbreaking solutions, these MedTech stocks should be on your radar. Via InvestorPlace This Visa Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Wednesday July 10, 2024 Via Benzinga Eye Disease-Focused Glaukos' 'Investor Interest Should Continue To Gain Momentum:' Analyst May 02, 2024 Glaukos reports Q1 adjusted EPS loss, sales beat estimates. Strong guidance for 2024 with positive analyst sentiment, driving stock up 6.22%. Via Benzinga Topics Earnings Exposures Financial C.H. Robinson Worldwide Posts Upbeat Results, Joins Avis Budget Group, Qualcomm, BorgWarner, Moderna And Other Big Stocks Moving Higher On Thursday May 02, 2024 Via Benzinga Glaukos: Q4 Earnings Insights February 21, 2024 Via Benzinga Earnings Scheduled For February 21, 2024 February 21, 2024 Companies Reporting Before The Bell • Gatos Silver (NYSE:GATO) is estimated to report quarterly earnings at $0.09 per share on revenue of $83.00 million. Via Benzinga Analyst Ratings For Glaukos February 16, 2024 Via Benzinga GKOS Stock Earnings: Glaukos Misses EPS, Beats Revenue for Q1 2024 May 01, 2024 GKOS stock results show that Glaukos missed analyst estimates for earnings per share but beat on revenue for the first quarter of 2024. Via InvestorPlace Signet Jewelers, Dave & Buster's Entertainment, Blue Owl Capital And Other Big Stocks Moving Higher On Wednesday April 03, 2024 U.S. stocks were higher, with the Dow Jones gaining over 50 points on Wednesday. Via Benzinga Topics Stocks Exposures US Equities Analog Devices To Rally Around 19%? Here Are 10 Top Analyst Forecasts For Thursday February 22, 2024 Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page. Via Benzinga Glaukos' Newly Approved Glaucoma Treatment Is The 'Biggest Driver To Watch': Analyst December 21, 2023 Shares of Glaukos Corp (NYSE: GKOS) continued to climb in early trading on Thursday, after the company’s iDose TR (travoprost intracameral implant) received U.S. Via Benzinga Unveiling 7 Analyst Insights On Glaukos December 21, 2023 Via Benzinga Analyst Ratings for Glaukos November 28, 2023 Via Benzinga 4 Analysts Have This to Say About Glaukos November 08, 2023 Via Benzinga 8 Analysts Have This to Say About Glaukos September 26, 2023 Via Benzinga Amazon.com To Rally Over 38%? Here Are 10 Top Analyst Forecasts For Thursday December 21, 2023 Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page. Via Benzinga iDoseTR Approval Sets Stage for Glaukos' Game-Changing Product, Surpassing Market Expectations, Says Analyst December 15, 2023 Thursday, the FDA approved Glaukos Corporation's (NYSE: GKOS) marketing application for a single administration per eye of iDose TR (travoprost intracameral implant) 75 mcg, a prostaglandin analog... Via Benzinga Exposures Product Safety Dow Extends Rally As Treasury Yields Tank December 14, 2023 The Dow Jones Industrial Average is charging full speed ahead, up 78 points this afternoon after yesterday closing at record highs, on the heels of the Federal Reserve's rate decision. Via Talk Markets Topics Economy Stocks Exposures Interest Rates US Equities FDA Approves Glaukos' Eye Implant To Treat Eye Pressure In Glaucoma Patients December 14, 2023 The FDA approved Glaukos Corporation's (NYSE: GKOS) marketing application for a single administration per eye of iDose TR (travoprost intracameral implant) 75 mcg, a prostaglandin analog indicated for... Via Benzinga Exposures Product Safety Glaukos's Earnings Outlook August 01, 2023 Via Benzinga < Previous 1 2 3 4 5 Next > Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.
